AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

LATHAM, N.Y.--(BUSINESS WIRE)--December 19, 2024-- 

AngioDynamics, Inc. $(ANGO)$, a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event.

Fiscal 2025 Second Quarter Financial Results Conference Call

The Company's management will host a conference call at 8:00 am ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).

This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, until Wednesday, January 15, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13750571.

Virtual NanoKnife Investor Event

In an effort to provide investors more insight into the NanoKnife System and the Company's strategy for the technology, the Company will be hosting a virtual investor event on January 8, 2025 at 9:30am ET.

This event be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company's innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241219061676/en/

 
    CONTACT:    Investors: 

AngioDynamics, Inc.

Stephen Trowbridge, Executive Vice President & CFO

(518) 795-1408

(END) Dow Jones Newswires

December 19, 2024 17:01 ET (22:01 GMT)